Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), has signed a collaboration agreement with Lonza, a global partner to the pharmaceutical, biotech and nutraceutical markets, which covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble AβOs for the treatment of AD, for clinical development and commercialization if appro...